Publications

Detailed Information

Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure

DC Field Value Language
dc.contributor.authorLim, Soo K.-
dc.contributor.authorGoh, Bak L.-
dc.contributor.authorVisvanathan, Ravindran-
dc.contributor.authorKim, Su H.-
dc.contributor.authorJeon, Jin S.-
dc.contributor.authorKim, Sung G.-
dc.contributor.authorChang, Jae H.-
dc.contributor.authorLim, Chun S.-
dc.contributor.authorMorad, Zaki-
dc.date.accessioned2022-03-21T04:10:55Z-
dc.date.available2022-03-21T04:10:55Z-
dc.date.issued2022-01-03-
dc.identifier.citationBMC Nephrology. 2022 Jan 03;23(1):14-
dc.identifier.urihttps://doi.org/10.1186/s12882-021-02651-0-
dc.identifier.urihttps://hdl.handle.net/10371/177079-
dc.titleCorrection to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure-
dc.language.rfc3066en-
dc.rights.holderThe Author(s)-
dc.date.updated2022-01-09T04:09:59Z-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share